Rates and Predictors of Failure of First-line Antiretroviral Therapy and Switch to Second-line ART in South Africa

Objectives: To measure rates and predictors of virologic failure and switch to second-line antiretroviral therapy (ART) in South Africa. Design: Observational cohort study. Methods: We included ART-naive adult patients initiated on public sector ART (January 2000 to July 2008) at 5 sites in South Africa who completed ≥6 months of follow-up. We estimated cumulative risk of virologic failure (viral load ≥400 copies/mL with confirmation above varying thresholds) and switching to second-line ART. Results: Nineteen thousand six hundred forty-five patients (29,935 person-years) had a median of 1.3 years of study follow-up (1.8 years on ART) and a median CD4 count of 93 (IQR: 39–155) cells per microliter at ART initiation. About 9.9% (4.5 per 100 person-years) failed ART in median 16 (IQR: 12–23) months since ART initiation, with median 2.7 months (IQR: 1.6–4.7) months between first elevated and confirmatory viral loads. By survival analysis, using a confirmatory threshold of 400 copies per milliliter, 16.9% [95% confidence interval (CI): 15.4% to 18.6%] failed by 5 years on ART, but only 7.8% (95% CI: 6.6% to 9.3%) using a threshold of 10,000. CD4 <25 versus 100–199 (adjusted HR: 1.60; 95% CI: 1.37 to 1.87), ART initiation viral load ≥1,000,000 versus <10,000, (1.32; 0.91 to 1.93), and 2+ gaps in care versus 0 (95% CI: 7.25; 4.95 to 10.6) were predictive of failure. Overall, 10.1% (95% CI: 9.0% to 11.4%) switched to second-line by 5 years on ART. Lower CD4 at failure and higher rate of CD4 decline were predictive of switch (decline 100% to 51% versus 25% to –25%, adjusted HR: 1.96; 95% CI: 1.35 to 2.85). Conclusions: In resource-limited settings with viral load monitoring, virologic failure rates are highly sensitive to thresholds for confirmation. Despite clear guidelines there is considerable variability in switching failing patients, partially in response to immunologic status and postfailure evolution.

[1]  Kara Wools-Kaloustian,et al.  Cohort Profile: the international epidemiological databases to evaluate AIDS (IeDEA) in sub-Saharan Africa. , 2012, International journal of epidemiology.

[2]  Richard Degerman,et al.  Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: randomised trial , 2011, BMJ : British Medical Journal.

[3]  B. Chi,et al.  Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in southern Africa , 2011, AIDS.

[4]  M. Egger,et al.  Virologic Failure and Second-Line Antiretroviral Therapy in Children in South Africa—The IeDEA Southern Africa Collaboration , 2011, Journal of acquired immune deficiency syndromes.

[5]  S. Lawn,et al.  Changes in Programmatic Outcomes During 7 Years of Scale-up at a Community-Based Antiretroviral Treatment Service in South Africa , 2011, Journal of acquired immune deficiency syndromes.

[6]  J. Mellors,et al.  Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa , 2010, AIDS research and treatment.

[7]  L. Myer,et al.  Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002–2007 , 2010, AIDS.

[8]  J. Eron,et al.  Second‐line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline * , 2010, HIV medicine.

[9]  J. Sterne,et al.  Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes , 2010, The Lancet.

[10]  M. Fox,et al.  High Rates of Survival, Immune Reconstitution, and Virologic Suppression on Second-Line Antiretroviral Therapy in South Africa , 2010, Journal of acquired immune deficiency syndromes.

[11]  N. Ford,et al.  Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa , 2010, AIDS.

[12]  M. Egger,et al.  Mortality after failure of antiretroviral therapy in sub‐Saharan Africa , 2010, Tropical medicine & international health : TM & IH.

[13]  M. Boyd.  Current and future management of treatment failure in low- and middle-income countries , 2010, Current opinion in HIV and AIDS.

[14]  V. DeGruttola,et al.  Non-nucleoside reverse transcriptase inhibitor outcomes among combination antiretroviral therapy-treated adults in Botswana , 2010, AIDS.

[15]  S. Reid,et al.  Diagnosis and management of antiretroviral-therapy failure in resource-limited settings in sub-Saharan Africa: challenges and perspectives. , 2010, The Lancet. Infectious diseases.

[16]  M. Egger,et al.  Accuracy of WHO CD4 cell count criteria for virological failure of antiretroviral therapy , 2009, Tropical medicine & international health : TM & IH.

[17]  M. Egger,et al.  Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring , 2009, AIDS.

[18]  B. Eley,et al.  Monitoring the South African National Antiretroviral Treatment Programme, 2003-2007: the IeDEA Southern Africa collaboration. , 2009, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[19]  J. V. van Oosterhout,et al.  Diagnosis of antiretroviral therapy failure in Malawi: poor performance of clinical and immunological WHO criteria , 2009, Tropical medicine & international health : TM & IH.

[20]  Elena Losina,et al.  HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme , 2009, Antiviral therapy.

[21]  T. Quinn,et al.  Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda , 2009, AIDS.

[22]  D. Westreich,et al.  Long term outcomes of antiretroviral therapy in a large HIV/AIDS care clinic in urban South Africa: a prospective cohort study , 2009, Journal of the International AIDS Society.

[23]  A. De Luca,et al.  Incidence and predictors of death, retention, and switch to second-line regimens in antiretroviral- treated patients in sub-Saharan African Sites with comprehensive monitoring availability. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  Julio S. G. Montaner,et al.  CD4+ T-Cell Count Monitoring Does Not Accurately Identify HIV-Infected Adults With Virologic Failure Receiving Antiretroviral Therapy , 2008, Journal of acquired immune deficiency syndromes.

[25]  Z. Fox,et al.  Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen , 2008, AIDS.

[26]  P. Mee,et al.  Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa , 2008, AIDS.

[27]  A. Calmy,et al.  Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières , 2008, AIDS.

[28]  B. Gazzard,et al.  Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression? , 2008, AIDS.

[29]  L. Fairall,et al.  Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy in South Africa , 2008 .

[30]  Summary TOWARDS UNIVERSAL ACCESS : Scaling up Priority HIV / AIDS Interventions in the Health Sector Progress Report , 2008 .

[31]  J. Crump,et al.  Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  P. Graaff,et al.  Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first- and second-line regimens , 2007, AIDS.

[33]  R. Chaisson,et al.  Adherence to Nonnucleoside Reverse Transcriptase InhibitorBased HIV Therapy and Virologic Outcomes , 2007, Annals of Internal Medicine.

[34]  B. Chi,et al.  Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. , 2006, JAMA.

[35]  B. Strom,et al.  Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy , 2006, AIDS.

[36]  N. Ford,et al.  Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment , 2006, The Lancet.

[37]  J. Robins,et al.  Comparison of dynamic treatment regimes via inverse probability weighting. , 2006, Basic & clinical pharmacology & toxicology.

[38]  B. Stilwell,et al.  Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision. , 2006 .

[39]  B. Gazzard,et al.  Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study , 2004, The Lancet.

[40]  P. Keiser,et al.  Comparison of Nevirapine- and Efavirenz-Containing Antiretroviral Regimens in Antiretroviral-Naïve Patients: A Cohort Study , 2002, HIV clinical trials.

[41]  M. Moroni,et al.  Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study. , 2002, The Journal of infectious diseases.

[42]  H. Boshuizen,et al.  Multiple imputation of missing blood pressure covariates in survival analysis. , 1999, Statistics in medicine.

[43]  D. Rubin.  Multiple Imputation After 18+ Years , 1996 .